[Efficacy and Safety of Polatuzumab Vedotin Combined with Chemotherapy in the Treatment of Relapsed and Refractory Diffuse Large B-Cell Lymphoma].

OBJECTIVE

To observe the efficacy and safety of polatuzumab vedotin (pola) combined with chemotherapy in the treatment of relapsed and refractory diffuse large B-cell lymphoma (R/R DLBCL).

METHODS

A total of 23 patients with R/R DLBCL treated at the First Affiliated Hospital of Zhejiang University and its Liangzhu Branch from April 2023 to March 2024 were retrospectively collected. All patients were treated with pola combined with chemotherapy regimens such as BR, R-GDP, R-CHOP, or other regimens.

RESULTS

All 23 patients were evaluable for efficacy, with 10 achieving complete response (CR), 7 partial response (PR), 3 stable disease (SD), and 3 progressive disease (PD). The most common adverse events included myelosuppression, fever, and pulmonary infection. No severe adverse events resulted in drug withdrawal.

CONCLUSION

Pola combined with chemotherapy demonstrates promising efficacy and a favorable safety profile in the treatment of R/R DLBCL.